Evidence map›Paper›PMID 27586161›Full record

ArticleJournal of neuroinflammation2016

Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome.

Lidia Sabater, Jesús Planagumà, Josep Dalmau, Francesc Graus

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Brain atrophy patterns in anti-IgLON5 disease.Brain : a journal of neurology · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Anti-IgLON5 Disease 10 Years Later: What We Know and What We Do Not Know.Neurology(R) neuroimmunology & neuroinflammation · 2025
    Review
  19. Review
  20. Recent advances in autoimmune encephalitis.Arquivos de neuro-psiquiatria · 2024
    Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lidia SabaterNeuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. lisabate@clinic.ub.es.ORCID 0000-0001-8556-6166
Jesús PlanagumàNeuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Josep DalmauNeuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Francesc GrausNeuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

Paraneoplastic Disorders of the CNS: Autoantigen ProfilingR01NS077851 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI DALMAU, JOSEP O. · 2011 to 2015
$1.9M
NINDS NIH HHS R01 NS077851
6 · The paper itself

Abstract

backgroundAntibodies against IgLON5, a neuronal adhesion protein of unknown function, are markers of a novel neurological disorder termed anti-IgLON5 syndrome. The disorder shows a remarkable association with the HLA-DQB1*0501 and HLA-DRB1*1001 alleles, and postmortem studies demonstrate a novel neuronal tauopathy predominantly involving the hypothalamus and tegmentum of the brainstem. The role of IgLON5 antibodies in the pathogenesis of the disease is currently unknown. Here, we have determined the target epitopes of IgLON5 antibodies, the effects of the IgLON5 antibodies in rat hippocampal neurons, and the IgG subclass responsible for these effects.

methodsHEK293 cells expressing several deletion constructs of IgLON5 were used to determine the epitopes recognized by the serum of 15 patients with anti-IgLON5 syndrome. The role of glycosylation in immunogenicity was tested with PNGase F treatment of transfected cells. Dissociated hippocampal neuronal cultures were used to test by immunocytochemistry the effects of total IgG, IgG1, and IgG4 subclasses of IgLON5 antibodies.

resultsPatients' antibodies reacted with the immunoglobulin-like domain 2 of IgLON5. Glycosylation was not required for immunoreactivity. The predominant subclass of IgLON5 antibodies was IgG4 but all patients also had IgG1. The mean percentage of specific IgLON5 IgG4 and IgG1 of the samples analyzed by flow cytometry was 64 and 33 %, respectively. In cultures of hippocampal neurons, patients' antibodies caused a decrease of cell surface IgLON5 clusters that was not reversed after IgLON5 antibodies were removed from the media. The decrease of surface IgLON5 clusters correlated with the rate of antibody internalization. These effects were observed with purified IgG1 but not with the IgG4 antibodies.

conclusionsIgLON5 antibodies recognize the immunoglobulin-like domain 2 of the antigen, and the reactivity is not dependent on glycosylation. The effects observed on hippocampal neuronal cultures indicate an irreversible antibody-mediated internalization of surface IgLON5. These effects were mediated by specific IgLON5 IgG1 antibodies and suggest a pathogenic role of these antibodies in the disease.

Indexed as

AnimalsAnimals, NewbornAutoimmune DiseasesCell Adhesion Molecules, NeuronalCells, CulturedEnzyme-Linked Immunosorbent AssayGlycosylationHEK293 CellsHippocampusHLA-DRB1 ChainsHumansImmunodominant EpitopesImmunoglobulin Fab FragmentsImmunoglobulin GMutationNeuronsCell Adhesion Molecules, NeuronalHLA-DRB1 ChainsIgLON5 protein, humanImmunodominant EpitopesImmunoglobulin Fab FragmentsImmunoglobulin GAutoantibodiesIgLON5Immunoglobulin subclassesTauopathy

Identifiers

PMID27586161
PMCPMC5007989
OpenAlexW2514674077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.